Combination of acute exacerbation of idiopathic nonspecific interstitial pneumonia and pulmonary embolism after booster anti-COVID-19 vaccination. (2022)

• Record Type: Journal Article
• Authors: Bocchino, Marialuisa; Rea, Gaetano; Buonocore, Anna; Lieto, Roberta; Mazzocca, Annalisa; Di Domenico, Arcangela; Stanziola, Anna A.
• Is Part Of: Respiratory medicine case reports. Volume 38(2022)
• Publication Date: 2022
• Subjects: SARS-CoV-2 anti-COVID-19 mRNA vaccination -- Acute exacerbation -- Pulmonary embolism -- Interstitial lung disease; COVID-19 Coronavirus disease 2019 -- ILD interstitial lung disease -- SARS-CoV-2 Severe Acute Respiratory Syndrome Coronavirus-2 -- AE acute exacerbation -- iNSIP idiopathic nonspecific interstitial pneumonia -- HRCT high-resolution computed tomography -- GGO ground glass opacity -- IPF idiopathic pulmonary fibrosis -- MIP maximum intensity projection; Respiratory organs -- Diseases -- Periodicals; Chest -- Diseases -- Periodicals; Respiratory Tract Diseases -- Periodicals; Respiratory System -- Periodicals; Chest -- Diseases; Respiratory organs -- Diseases; Electronic journals; Periodicals; 616.2
• DOI: 10.1016/j.rmcr.2022.101674
• Languages: English
• ISSNs: 2213-0071

Abstract

Abstract: Coronavirus disease-2019 (COVID-19) is a systemic disorder with the lung and the vasculature being the preferred targets. Patients with interstitial lung diseases represent a category at high risk of progression in the case of Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV)-2 infection, and as such deserve special attention. We first describe the combination of acute exacerbation and pulmonary embolism in an elderly ILD patient after booster anti-COVID-19 mRNA vaccination. Vaccines availability had significantly and safety impacted COVID-19 morbidity and mortality worldwide. Immunization against COVID-19 is indisputable but must not be separated from the awareness of potential adverse effects in fragile patients.